Elevated acetate levels correlate with optimal response to ocrelizumab treatment in low inflammatory primary progressive MS patients
J. I. Fernandez Velasco,E. Monreal,J. Kuhle,V. Meca-Lallana,J. Meca-Lallana,G. Izquierdo,C. Oreja-Guevara, F. Gascon-Gimenez,S. Sainz De la Maza, P. E. Walo-Delgado, P. Lapuente-Suanzes,A. Maceski,E. Rodriguez-Martin,E. Roldan,N. Villarrubia,A. Saiz,Y. Blanco,C. Diaz-Perez,G. Valero-Lopez,J. Diaz-Diaz,Y. Aladro,L. Brieva,C. Iniguez,I. Gonzalez-Suarez,L. A. Rodriguez De Antonio,J. M. Garcia-Dominguez, J. Sabin,S. Llufriu,E. Garcia-Calvo, A. Machuca,J. L. Luque-Garcia,J. Masjuan,L. Costa-Frossard,L. M. Villar MULTIPLE SCLEROSIS JOURNAL(2022)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)